Down 20% on Oct 23, and still 30% under its Oct 22 close.
Up 226% over the five years to Nov 9 while the S&P 500 rose 72%; down 20% on Oct 23.
4 reasons, from its filings, with the timeline and its peers, for Pro members.
CORT's Quality Score fell 2 points on Tue, Nov 10, to 7. It closed away from its high of the day (2 chart checks stopped).
Follow CORT's trial news. Pro members can get an alert when Corcept Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| The company | Sales up 30% on the year |
| Latest filing | 8-K, Nov 3 |
Expected to report Wed Feb 24, after the close
No shelf registration or at-the-market program on file in the last three years.
President, Oncology Roberto Wandenkolk Vieira sold 8,333 shares on Nov 2, under a planned sale. 43 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
CORT is #61 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 61 |
Net income over four quarters: CORT $162M, ONC $916M.
Expected to report Wed Feb 24, after the close (in 106 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A profit of $1.01 a share, from $0.16.
CORT's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Revenue | $1.1B to $1.2B |
Sales grew 17% a year over 5 years, fiscal 2020 to 2025.
Its share count fell 0.7% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 3, 2026 | +3.7% | -3.3% | -10.5% |
| Jul 29, 2026 | +20.5% | +27.3% | +19.1% |
| Apr 30, 2026 | +4.2% | +10.5% | +9.7% |
Sales grew every year from 2018 to 2025, to $761M. It made a profit in each of the eight years.
RSI 25.0, MACD below signal, below both averages. Not scored.
4 insiders sold $6.6M across 5 filings in the last 6 months. No open-market buys on record. The newest:
3 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: CORT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
“Our Products compete with established treatments, including surgery, radiation and other medications approved by the FDA for the treatment of patients with Cushing’s syndrome.”
CORT scores 7 today, which Breakaway calls Average. It is #61 of 281 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 20% on Oct 23, and still 30% under its Oct 22 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
CORT scores 7 today, which Breakaway calls Average (6 to 10). That is #61 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CORT's 7.
4 insiders sold $6.6M across 5 filings in the last 6 months. No open-market buys on record. The newest is Kimberly Park, Director, who sold $3.3M on Aug 26. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.